Subtype
Malignant Pleural Neoplasm
CI-CAN-00001168Explore in graph →
26 active trials4 approved drugs6 evidence items
- NCIt
- C3547
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001168Explore in graph →
Clinical trials
124 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (18)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05647265 | Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma | recruiting | Phase 2 | 26 | Alliance for Clinical Trials in OncologyOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT05765084 | Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma(Immuno-MESODEC) | recruiting | Phase 1 / Phase 2 | 15 | University Hospital, AntwerpOTHER |
| 1 |
| Jun 5, 2026 |
| clinicaltrials |
| NCT04400539 | The IMmunotherapy Pleural 5-ALA PDT(IMPALA) | recruiting | Phase 2 | 20 | University Hospital, LilleOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT07121374 | NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study(NECIM) | recruiting | Phase 1 / Phase 2 | 37 | University Hospital, AntwerpOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT05188859 | First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma | recruiting | Phase 2 | 29 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 31, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Aug 5, 2026source: clinicaltrials